SHORTWAVE LIFE SCIENCES PLC

("Shortwave" or "the Company")

 29 July 2025

      £250,000 Placing at £0.0025 per share

Appointment of Company Directors and Adviser

Comprehensive Business Review to Drive Company Repositioning

Shortwave Life Sciences PLC (PSY) listed on the Aquis Stock Exchange Growth Market, the UK's leading healthcare company focused on developing innovative treatments for anorexia nervosa, is pleased to announce the placing of 100,000,000 ordinary shares of £0.001 ("Placing Shares") at a price of £0.0025 per share ("Placing Price"), raising £250,000 ("Placing"). As part of the Placing, the Company has granted one warrant for every one new Placing Share subscribed for, exercisable at a price of £0.005 pence per share, valid until 5^th July 2027. The placing has been completed at a premium of 150% on the closing bid share price of 28 July 2025.

The Company will also issue 48,316,000 new ordinary shares to suppliers in lieu of cash fees, at the Placing Price, with one warrant granted on the same terms as the Placing.

The funds raised will be used to undertake a comprehensive business review, with the aim of establishing a strategic framework to:

·      Strengthen and grow the Company's core operating business.

·      Establish a Digital Asset Treasury Management function to support the operational Company funding requirements.

Board Appointments

To enable the business review, the Company announces the following Board appointments.

The Company is pleased to announce the appointment of Stephen John Molloy, aged 50, as a Non-Executive Director with immediate effect. Stephen will be charged with a specific focus on guiding the Company in setting up a Digital Asset Management Treasury function.

Stephen Molloy, Non-Executive Director, has spearheaded and established innovative digital media and technology businesses globally over more than 27 years. He excels in scaling companies from the ground up. Stephen specialises in identifying emerging technologies that challenge traditional industry paradigms.

Recognising the transformative impact of blockchain technology, he earned a Blockchain Business Strategy qualification from Oxford in 2018. Since then, his focus has been on research and investments in digital assets, he is actively involved with regulatory developments in the digital asset ecosystem ensuring adherence to the evolving legal frame works and industry standards.

Stephen is Managing Parter at MP Alpha Holdings Ltd.

Mr. Molloy does not currently hold any ordinary shares in the Company. The below details all directorships held by the director in any other company at any time in the previous five years:

The Company is pleased to also appoint Rolf Ad Gerritsen, aged 62, to the Board as Executive Chairman with immediate effect to spearhead the business review and drive the Company's accelerated growth trajectory.

Rolf Gerritsen, Executive Chairman, an entrepreneurial executive, with outstanding strategic, organisational, commercial and financial skills with an exceptional delivery record developed over the last 30 years. His core strengths included strategy development, implementation and sourcing capital for growth companies, special situations and restructuring opportunities.

Rolf has a proven ability to develop creative solutions to complex business issues. With his international experience, 4 languages spoken fluently, having worked in Europe, the USA, Africa, Australia, Middle East, the Far East and South America, Rolf has an exceptional network of business contacts that he stays in close contact with and shares development ideas on a regular basis.

Over the last few years Rolf has been working with Boards of listed companies developing, designing and implementing growth strategies while ensuring the appropriate capital is sourced to deliver the plans and the regulatory and compliance requirements are adhered to.

Mr. Gerritsen does not currently hold any ordinary shares in the Company. Rolf will receive 10,000,000 new Ordinary Shares as part of his appointment, representing approximately 1.76% of the enlarged issued share capital. The below details all directorships held by the director in any other company at any time in the previous five years:

Except as set out above, there is no further information regarding either Stephen Molloy or Rolf Gerritsen, that is required to be disclosed pursuant to Rule 4.9 of the Aquis Growth Market Access Rulebook.

Existing Board members will remain in place with Stephen Murphy focusing on the development of the business, Rivki Stern continuing to oversee the operational business and Ron Lipsky, Non-Executive Director, as an independent Board member.

Adviser Appointment

The appointment of Stefania Barbaglio as a special advisor to the Board guiding the Board through digital asset strategy, marketing and business review.

Stefania Barbaglio, proposed Strategic Advisor to the Board, is a British-Italian entrepreneur, investor, and strategic advisor with over 15 years' experience in capital markets and a decade working at the forefront of the crypto industry. A respected early advocate of Bitcoin, she is widely recognised as one of the UK's most influential female voices in digital assets.

Stefania has advised dozens of private and listed companies on investor relations, fundraising, and strategic communications, including successful IPOs on the London Stock Exchange. She is the founder of Cassiopeia, a UK-based consultancy supporting high-growth companies through public market transitions and disruptive innovation.

Over the past 10 years, Stefania has built a powerful international network across the crypto, tech, and investment sectors. Her work spans investment, policy, and strategy. She is a trusted connector and thought leader, known for her ability to bridge founders, investors, institutions, and media.

She hosts FinancialFox, a leading crypto and tech media platform featuring interviews with global innovators and is a regular speaker and moderator at major crypto and investment events. Her insights have been featured in CoinDesk, Yahoo Finance, and other top-tier financial media.

Admission

Application will be made for the 158,316,000 new Ordinary Shares to be admitted to trading on the Aquis Growth Market ("Admission"). It is expected that Admission of the new ordinary shares will become effective on or around 8.00 a.m. on or around 4 August 2025. 

Total Voting Rights 

Following Admission of the Placing Shares, the Company's total number of Ordinary Shares in issue will be 568,606,762 with voting rights. The Company does not hold any Ordinary Shares in treasury. The figure of 568,606,762 Ordinary Shares may therefore be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.

About Shortwave Life Sciences:

Shortwave Life Sciences is a developer of breakthrough therapies addressing unmet medical needs in mental health. The Company is committed to the advancement of innovative solutions through drug development, with a mission to pioneer breakthrough therapies that transform the landscape of mental health care. With a team of dedicated experts and a commitment to innovation, Shortwave Life Sciences is uniquely positioned to introduce and develop solutions for the complex challenges of mental health disorders worldwide.

The Directors of the Company accept responsibility for the contents of this announcement.

For media inquiries, please contact:

Enquiries:

Company:

Rolf Gerritsen

+ 44 (0) 7766 916 557

Peterhouse Capital Limited:

Corporate Adviser:

+ 44 (0) 20 7469 0930

Corporate Broker:

+44 (0) 20 7220 9797